SCOPUS 정보 검색 플랫폼

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 6, 2014, Pages 581-582

The ISoP standards and best practices committee

(6) Bruno, R a Mentre F b Tannenbaum, S c Wang, Y d Corrigan, B e Mager, D E f

a A Certara Company (France)

b UNIVERSITÉ PARIS DIDEROT (France)

c ASTELLAS PHARMA GLOBAL DEVELOPMENT (United States)

d CENTER FOR DRUG EVALUATION AND RESEARCH (United States)

e PFIZER GLOBAL RESEARCH AND DEVELOPMENT (United States)

f UNIVERSITY AT BUFFALO (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; DRUG INDUSTRY; DRUG UTILIZATION; EUROPEAN MEDICINES AGENCY; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; PHARMACY AND THERAPEUTICS COMMITTEE; PRIORITY JOURNAL; REVIEW;

GUIDELINES AS TOPIC; MODELS, STATISTICAL; PHARMACOKINETICS; PHARMACOLOGY; POPULATION;

EID: 84901022577 PISSN: 00099236 EISSN: 15326535 Source Type: Journal
DOI: 10.1038/clpt.2014.65 Document Type: Review

Times cited : (3)

References (6)

1
- 78449279738
- Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry
- Stone, J. et al. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J. Clin. Pharmacol. 50, 20S-30S (2010
- (2010) J. Clin. Pharmacol , vol.50
- Stone, J.¹

2
- 77954868608
- Ascpt task force for advancing pharmacometrics and integration into drug development
- Goldberger, M.J. et al. ASCPT task force for advancing pharmacometrics and integration into drug development. Clin. Pharmacol. Ther. 88, 158-161 (2010
- (2010) Clin. Pharmacol. Ther , vol.88 , pp. 158-161
- Goldberger, M.J.¹

3
- 78449277532
- Defining the future of pharmacometrics: The american society of pharmacometrics
- Pfister, M. et al. Defining the future of pharmacometrics: The American Society of Pharmacometrics. J. Clin. Pharmacol. 50, 158S (2010
- (2010) J. Clin. Pharmacol , vol.50
- Pfister, M.¹

4
- 84881167230
- Establishing best practices and guidance in population modeling: An experience with an internal population pharmacokinetic analysis guidance
- Byon, W. et al. Establishing best practices and guidance in population modeling: An experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacomet. Syst. Pharmacol. 2, e51 (2013
- (2013) CPT Pharmacomet. Syst. Pharmacol , vol.2
- Byon, W.¹

5
- 84881145785
- Best practices in population modeling should always be evolving
- Karlsson, M.O. & Mentré, F. Best practices in population modeling should always be evolving. CPT Pharmacomet. Syst. Pharmacol. 2, e52 (2013
- (2013) CPT Pharmacomet. Syst. Pharmacol , vol.2
- Karlsson, M.O.¹ Mentré, F.²

6
- 85083120896
- European Medicines Agency. 24 June 2013
- European Medicines Agency. Policy 0070: Publication and access to clinical-Trial data. Draft for public consultation http://www.ema. europa.eu/docs/en-GB/document-library/Other/2013/06/WC500144730.pdf (24 June 2013
- Policy 0070: Publication and access to clinical-Trial data Draft for public consultation

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.